ProQR Therapeutics Creating RNA therapies for patients in need
On a mission
At ProQR, we are passionate about pushing the boundaries of science and technology to create innovative solutions for unmet medical needs. Our team is dedicated to conducting cutting-edge research and development in the RNA editing field to improve the lives of patients and families affected by genetic disorders.
We believe that every person deserves access to the best possible care, and we are committed to working together as a community to make that happen. Join us on our mission to make a real difference in the lives of those we serve.
Our science
Internal link Working at ProQRLatest press releases
-
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
-
Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
-
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
ProQR Community News
-
ProQR recognised as a Great Place To Work
Community news
-
Embracing Diversity: Why it Matters
Community news
-
Exploring why companies partner their technology
Community news
ProQR & Eli Lilly and Company partnership
Since 2021 ProQR has partnered with Eli Lilly and Company focusing on the discovery, development, and commercialization of potential new using ProQR’s proprietary Axiomer® RNA editing platform.
Internal link Read about our partnership
Meet us at
-
Internal link Raymond James Biotech Innovation Symposium
Investor conference -
Internal link Van Lanschot Kempen Life Sciences Conference
Investor conference